All In Biotech

Drug Trial Radar · NCT05363215

A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants

A Phase 1, Open-label, Parallel-group Study to Assess the Pharmacokinetics, Safety, and Tolerability of S-217622 in Participants With Mild, Moderate, and Severe Renal Impairment and Healthy Control Participants

Last checked: Nov 20, 2026Latest source record: Apr 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Aug 10, 2022

Primary completion

Apr 12, 2023

Study completion Apr 12, 2023

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
May 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to measure the PK, safety, and tolerability of S-217622 in participants with mild, moderate, or severe renal impairment and in those with normal renal function.

Conditions

  • Renal Impairment

Interventions

  • S-217622Drug

    Tablet for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
  2. Time to Maximum Plasma Concentration (Tmax) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
  3. Area Under the Plasma Concentration-Time Curve (AUC) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
  4. Terminal Elimination Half-Life (t1/2,z) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
  5. Terminal Elimination Rate Constant (λz) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
  6. Mean Residence Time (MRT) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
  7. Apparent Total Clearance (CL/F) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
  8. Apparent Volume of Distribution (Vz/F) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
  9. Renal Clearance (CLR) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
  10. Fraction of Dose Excreted in Urine (Feu) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
  11. Fraction Unbound in Plasma (FU) of S217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Pharmacology of Miami, LLC

    Miami, Florida

  • Advanced Pharma CR, LLC

    Miami, Florida

  • Orlando Clinical Research Center, Inc.

    Orlando, Florida

  • Nucleus Network

    Saint Paul, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.